Patent ID: 8435748

Claim:
A method of diagnosing cancer in a subject in need thereof, comprising: 1) measuring expression of des-R-prothrombin activation peptide fragment F2 in samples selected from the group consisting of blood, serum and plasma, which are respectively obtained from a test subject and a normal subject, wherein the measuring is conducted by a method selected from the group consisting of: 2-dimensional gel electrophoresis; ESI-Q-TOF MS (Electrospray Ionisation Quadrupole-Time-of-Flight Mass Spectrometry); MALDI-TOF MS (Matrix-Assisted Laser Desorption and Ionization Time-of-Flight Mass Spectrometry); SELDI-TOF MS (Surface-Enhanced Laser Desorption and Ionization Time-of-Flight Mass Spectrometry); a kit or biochip containing antibodies specifically binding to des-R prothrombin activation peptide fragment F2; 2) comparing the measured expression level of des-R-prothrombin activation peptide fragment F2 in the sample of the test subject with that of the normal subject, and selecting a test subject demonstrating reduced des-R-F2 expression; and 3) determining that the test subject selected at step 2) has a cancer.